Vogt-Koyanagi-Harada (VKH) disease is a systemic immune disorder. Clinical manifestations and treatment challenges differ between individuals experiencing the initial-onset and those with recurrent VKH. Profiling mRNA and proteins in VKH patients at various stages has the potential to reveal novel treatment targets, particularly for individuals in the recurrent stage.